Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Adaptimmune
Sponsor:
Information provided by (Responsible Party):
Adaptimmune
ClinicalTrials.gov Identifier:
NCT01350401
First received: May 2, 2011
Last updated: July 11, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2031
  Estimated Primary Completion Date: May 2021 (Final data collection date for primary outcome measure)